SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense volatility as investors weigh a double earnings beat against a lowered revenue outlook, with the community sharply divided between those calling for a long-term turnaround and those betting on further downside. Sentiment remains polarized, with active debate over the brand's 'woke' image, competition from newer athletic brands, and whether the stock's current valuation represents a generational buying opportunity or a deeper structural decline.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market digests strong June delivery figures alongside aggressive growth in its premium SUV segment, despite persistent concerns over guidance accuracy and sector-wide volatility. Investors are actively debating the company's long-term profitability and the impact of the ongoing competition with rivals like Li Auto and Xpeng within a saturated Chinese EV landscape.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing renewed investor interest as the software sector undergoes a rotation, fueled by insider buying, strong institutional block orders, and a shifting narrative that enterprise AI will complement rather than disrupt existing platforms. The community is actively discussing a potential rebound as the stock shows technical strength, with many focusing on the upcoming quarterly results and the company's role as a key orchestrator in enterprise AI.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as investors react to a quarterly report that showed strong revenue growth and a shift to profitability, despite continued volatility and short-selling pressure. The community is actively debating the stock's long-term potential compared to peers and focusing on upcoming court rulings as a major potential catalyst.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant bearish pressure as investors express frustration over a lack of new enterprise contract catalysts and ongoing concerns regarding cash burn and dilution. Despite community debates over the company's long-term potential in voice and Agentic AI, heavy short interest remains a primary focal point, leaving traders divided between those accumulating at lower price levels and others concerned about the stock's persistent lack of upward momentum.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as the U.S. Department of Energy approved the Documented Safety Analysis for the company's Groves Isotope Test Reactor, a significant milestone moving the facility toward final pre-startup review. Community discussions are highly polarized, with many investors focused on the potential for a July criticality event as a major catalyst, while others express frustration over technical weakness and dilution concerns.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently experiencing high volatility following its inclusion in the Russell 1000 index, with investors debating whether the sharp pullback is a technical rebalancing event or a sign of overvaluation. The community remains focused on the company's long-term potential as a critical power infrastructure provider for AI data centers, weighing this against concerns over its negative earnings and rapid price fluctuations.

General Mills, Inc. engages in the manufacture of food. Its portfolio of brands includes household names like Cheerios, Nature Valley, Blue Buffalo, Häagen-Dazs, Old El Paso, Pillsbury, Betty Crocker, Totino’s, Annie’s, Wanchai Ferry and more. It operates through the following segments: North America Retail, International, North America Pet, and North America Foodservice. The North America Retail segment includes grocery stores, mass merchandisers, membership stores, natural food chains, drug, dollar and discount chains, convenience stores, and e-commerce grocery providers. The International segment refers to the retail and foodservice businesses outside of the US and Canada. The North America Pet segment includes pet food products sold in national pet superstore chains, e-commerce retailers, grocery stores, regional pet store chains, mass merchandisers, and veterinary clinics and hospitals. The North America Foodservice segment offers ready-to-eat cereals, snacks, refrigerated yogurt, frozen meals, unbaked and fully baked frozen dough products, baking mixes, and bakery flour. The company was founded by Cadwallader C. Washburn on June 20, 1928 and is headquartered in Minneapolis, MN.

General Mills, Inc.

General Mills is trending as investors debate the stock's long-term value against a backdrop of earnings that met expectations and a new, ambitious three-year productivity plan aimed at significant cost savings. The community is sharply divided, with some actively accumulating shares to capture the high dividend yield and defensive brand moat, while others remain skeptical, citing ongoing concerns about consumer demand shifts and a lack of insider buying.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as investors speculate on an imminent business combination following the company's recent filing of change-of-control severance agreements. Community sentiment remains highly bullish, with many participants pointing to the delayed accumulation of clinical events in the REGAL trial as a positive indicator of prolonged patient survival, while dismissing bearish hit pieces as coordinated short-selling FUD.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant bullish sentiment driven by the recent commercial launch of the BYOOVIZ biosimilar and strong script growth for the dry eye treatment VEVYE. Community members are increasingly focused on the company's platform expansion and the potential for a massive revenue ramp-up as it strengthens its position in the retina and specialty pharmaceutical markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

S&P 500, Nasdaq And Dow Close At Record Highs Amid Positive Reports Of US-Iran Ceasefire Negotiations —  IBM, SNOW, CZR, AKTX, LLY In Focus

Equity

U.S. and Iranian negotiators agreed on a 60-day memorandum of understanding to extend the ceasefire, media reports suggested.

AKTX Stock Shoots 50% Higher To Head Toward Best Month In Nearly 11 Years – What’s Fueling This Super Rally?

Akari Therapeutics’ CEO Abizer Gaslightwala highlighted the potential of the company’s proprietary platform to treat cancer ahead of ASCO 2026.

VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.read more...

Why Akari Therapeutics Stock Is Falling On Tuesday?

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.read more...

Akari Therapeutics Stock Jumps On Promising Preclinical Data

Akari Therapeutics shares are surging after preclinical data showed AKTX101 synergized with KRAS inhibition in pancreatic cancer models.read more...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside 

Akari said its experimental therapy AKTX-101 showed strong results when paired with an already-approved cancer drug in lab tests on pancreatic cancer cells that carry a common KRAS mutation.


The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Why Akari Therapeutics Stock Is Surging On Thursday?

Akari Therapeutics PLC (NASDAQ:AKTX) sees stock growth fueled by Q1 2026 earnings optimism and a new European patent for its PH1 ADC payload.read more...

This account has been verified as an official AKTX representative.

Verified Account

Akari Therapeutics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

AKTXAkari Therapeutics

Latest AKTX News